J&J's Xarel­to, Amar­in's Vas­cepa are cost-ef­fec­tive, not bud­get friend­ly — ICER

ICER, an in­creas­ing­ly in­flu­en­tial cost-ef­fec­tive­ness watch­dog in the Unit­ed States, has con­clud­ed in its re­view of treat­ments for car­dio­vas­cu­lar dis­ease that while the cost of J&J’s Xarel­to and Amarin’s Vas­cepa meet its bench­mark for val­ue pric­ing — the two treat­ments will not like­ly treat as many pa­tients as hoped with­out sur­pass­ing the an­nu­al bud­get thresh­old cal­cu­lat­ed by ICER for each ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER